- TOP
- Research＆Development
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to human health and well-being worldwide through innovative drug discovery and global commercialization, driven by state-of-the-art antibody technologies, in the core therapeutic areas of oncology, nephrology, central nervous system and immunology.
Kyowa Kirin is kidney disease drugs development of the world’s leading companies, development and launch a series of products in the field.In China, kidney disease listed in the field of medicine has treatment of renal anemia ESPO®（Recombinant Human Erythropoietin (CHO Cell) ）、NESP®of the treatment of dialysis patients with secondary parathyroid function already REGPARA ®(Cinacalcet Hydrochloride Tablets), the treatment of complications of chronic kidney disease in China has made a contribution
Kyowa Kirin in the global scope listed in the field of gene recombinant drugs, and using our unique technology development manufacturing of antibody drugs. In China, through blood cancer chemotherapy restrain neutropenia GRAN® (recombinant human granulocyte stimulating factor injection), contributing to the struggle of people with cancer.
In this field, Kyowa Kirin allergic disease treatment, ulcerative colitis therapy, etc. In recent years, in dermatology also developed and launched new products in China, LUMCIEF® (brawley especially single resistance injection) approved for the treatment of patients with psoriasis provides a new choice, for Chinese patients with psoriasis cure and contribute to the improvement of life quality.
In China, our company products not yet on the market the treatment field. But Kyowa Kirin group of the development in this area and the treatment of Parkinson’s disease drugs, antiepileptic drugs, contributing to the field of central nervous disease.
